Novel  	Novel  	 NNP	B-NP
Once-Daily  	Once-Daily  	 NNP	I-NP
Extended-Release  	Extended-Release  	 NNP	I-NP
Tacrolimus  	Tacrolimus  	 NNP	I-NP
Versus  	Versus  	 NNP	O
Twice-Daily  	Twice-Daily  	 NNP	B-NP
Tacrolimus  	Tacrolimus  	 NNP	I-NP
in  	in  	 IN	O
De  	De  	 NNP	B-NP
Novo  	Novo  	 NNP	I-NP
Kidney  	Kidney  	 NNP	I-NP
Transplant  	Transplant  	 NNP	I-NP
Recipients 	Recipients 	 NNP	I-NP
:  	:  	 :	O
Two-Year  	Two-Year  	 JJ	B-NP
Results  	Results  	 NNS	I-NP
of  	of  	 IN	O
Phase  	Phase  	 NNP	O
3 	3 	 CD	O
,  	,  	 ,	O
Double-Blind 	Double-Blind 	 NNP	B-NP
,  	,  	 ,	O
Randomized  	Randomized  	 NNP	O
Trial  	Trial  	 NNP	O
1-year  	1-year  	 NNP	O
data  	data  	 NNS	O
from  	from  	 IN	O
this  	this  	 DT	O
trial  	trial  	 NN	O
showed  	showed  	 VBD	O
the  	the  	 DT	O
noninferiority  	noninferiority  	 NN	B-NP
of  	of  	 IN	I-NP
a  	a  	 DT	I-NP
novel  	novel  	 NN	I-NP
once-daily  	once-daily  	 JJ	I-NP
extended-release  	extended-release  	 JJ	I-NP
tacrolimus  	tacrolimus  	 NNS	I-NP
( 	( 	 -LRB-	O
LCPT 	LCPT 	 NNP	B-NP
;  	;  	 :	O
Envarsus  	Envarsus  	 NNP	B-NP
XR 	XR 	 NNP	I-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
immediate-release  	immediate-release  	 JJ	B-NP
tacrolimus  	tacrolimus  	 NNS	I-NP
( 	( 	 -LRB-	O
IR-Tac 	IR-Tac 	 NNP	B-NP
)  	)  	 -RRB-	O
twice  	twice  	 RB	O
daily  	daily  	 JJ	O
after  	after  	 IN	O
kidney  	kidney  	 NN	B-NP
transplantation 	transplantation 	 NN	I-NP
.  	.  	 .	O
Final  	Final  	 JJ	O
24-month  	24-month  	 JJ	O
analysis  	analysis  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
2-armed 	2-armed 	 NNP	O
,  	,  	 ,	O
parallel-group 	parallel-group 	 NNP	B-NP
,  	,  	 ,	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
double-blind 	double-blind 	 NNP	B-NP
,  	,  	 ,	O
double-dummy 	double-dummy 	 NNP	B-NP
,  	,  	 ,	O
multicenter 	multicenter 	 NN	B-NP
,  	,  	 ,	O
phase  	phase  	 NN	O
3  	3  	 CD	O
trial.  	trial.  	 CD	O
543  	543  	 CD	O
de  	de  	 IN	B-NP
novo  	novo  	 JJ	I-NP
kidney  	kidney  	 NN	I-NP
recipients  	recipients  	 NNS	I-NP
randomly  	randomly  	 RB	O
assigned  	assigned  	 VBN	O
to  	to  	 TO	O
LCPT  	LCPT  	 NNP	B-NP
( 	( 	 -LRB-	O
n=268 	n=268 	 NNP	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
IR-Tac  	IR-Tac  	 NNP	B-NP
( 	( 	 -LRB-	O
n=275 	n=275 	 NNP	O
) 	) 	 -RRB-	O
;  	;  	 :	O
507  	507  	 CD	O
( 	( 	 -LRB-	O
93.4 	93.4 	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
completed  	completed  	 VBD	O
the  	the  	 DT	O
24-month  	24-month  	 JJ	O
study 	study 	 NN	O
.  	.  	 .	O
LCPT  	LCPT  	 NNP	B-NP
tablets  	tablets  	 NNS	I-NP
once  	once  	 RB	O
daily  	daily  	 JJ	O
at  	at  	 IN	O
0.17  	0.17  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg 	kg 	 CD	I-NP
/ 	/ 	 CD	I-NP
d  	d  	 NNS	I-NP
or  	or  	 CC	O
IR-Tac  	IR-Tac  	 JJ	B-NP
twice  	twice  	 RB	O
daily  	daily  	 JJ	O
at  	at  	 IN	O
0.1  	0.1  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg 	kg 	 CD	I-NP
/ 	/ 	 CD	I-NP
d 	d 	 SYM	I-NP
;  	;  	 :	O
subsequent  	subsequent  	 JJ	O
doses  	doses  	 NNS	O
were  	were  	 VBD	O
adjusted  	adjusted  	 VBN	O
to  	to  	 TO	O
maintain  	maintain  	 VB	O
target  	target  	 NN	B-NP
trough  	trough  	 NN	I-NP
ranges  	ranges  	 NNS	I-NP
( 	( 	 -LRB-	O
first  	first  	 JJ	O
30  	30  	 CD	O
days 	days 	 NNS	O
,  	,  	 ,	O
6-11  	6-11  	 FW	O
ng 	ng 	 FW	B-NP
/ 	/ 	 FW	I-NP
mL 	mL 	 FW	I-NP
;  	;  	 :	O
thereafter 	thereafter 	 RB	O
,  	,  	 ,	O
4-11  	4-11  	 FW	O
ng 	ng 	 FW	B-NP
/ 	/ 	 FW	I-NP
mL 	mL 	 FW	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
intervention  	intervention  	 NN	B-NP
was  	was  	 VBD	O
24  	24  	 CD	O
months 	months 	 NNS	O
;  	;  	 :	O
the  	the  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
double  	double  	 JJ	O
blinded  	blinded  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
entirety 	entirety 	 NN	O
.  	.  	 .	O
Treatment  	Treatment  	 NN	B-NP
failure  	failure  	 NN	I-NP
( 	( 	 -LRB-	O
death 	death 	 NN	O
,  	,  	 ,	O
transplant  	transplant  	 JJ	B-NP
failure 	failure 	 NN	I-NP
,  	,  	 ,	O
biopsy-proven  	biopsy-proven  	 JJ	B-NP
acute  	acute  	 JJ	O
rejection 	rejection 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
loss  	loss  	 NN	O
to  	to  	 TO	O
follow  	follow  	 VB	O
up 	up 	 RP	O
)  	)  	 -RRB-	O
within  	within  	 IN	O
24  	24  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
Safety  	Safety  	 NN	O
end  	end  	 NN	O
points  	points  	 NNS	O
included  	included  	 VBD	O
adverse  	adverse  	 JJ	O
events 	events 	 NNS	O
,  	,  	 ,	O
serious  	serious  	 JJ	O
adverse  	adverse  	 JJ	O
events 	events 	 NNS	O
,  	,  	 ,	O
new-onset  	new-onset  	 JJ	B-NP
diabetes 	diabetes 	 NN	I-NP
,  	,  	 ,	O
kidney  	kidney  	 NN	O
function 	function 	 NN	O
,  	,  	 ,	O
opportunistic  	opportunistic  	 JJ	B-NP
infections 	infections 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
malignancies 	malignancies 	 NN	O
.  	.  	 .	O
Pharmacokinetic  	Pharmacokinetic  	 JJ	B-NP
measures  	measures  	 NNS	I-NP
included  	included  	 VBD	O
total  	total  	 JJ	B-NP
daily  	daily  	 JJ	I-NP
dose  	dose  	 NN	I-NP
( 	( 	 -LRB-	O
TDD 	TDD 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
study  	study  	 NN	B-NP
drugs  	drugs  	 NNS	I-NP
and  	and  	 CC	O
tacrolimus  	tacrolimus  	 JJ	B-NP
trough  	trough  	 NN	I-NP
levels.  	levels.  	 CD	I-NP
24-month  	24-month  	 JJ	O
treatment  	treatment  	 NN	B-NP
failure  	failure  	 NN	I-NP
was  	was  	 VBD	O
LCPT 	LCPT 	 NNP	B-NP
,  	,  	 ,	O
23.1 	23.1 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
IR-Tac 	IR-Tac 	 NNP	B-NP
,  	,  	 ,	O
27.3 	27.3 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
treatment  	treatment  	 NN	B-NP
difference 	difference 	 NN	I-NP
,  	,  	 ,	O
-4.14 	-4.14 	 CD	O
%  	%  	 NN	O
[ 	[ 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
-11.38 	-11.38 	 CD	O
%  	%  	 NN	O
to  	to  	 TO	O
+3.17 	+3.17 	 CD	O
% 	% 	 NN	O
] 	] 	 -RRB-	O
,  	,  	 ,	O
well  	well  	 RB	O
below  	below  	 IN	O
the  	the  	 DT	O
+10 	+10 	 JJ	O
%  	%  	 NN	O
noninferiority  	noninferiority  	 NNS	B-NP
criterion  	criterion  	 VBP	I-NP
defined  	defined  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	O
12-month  	12-month  	 JJ	O
end  	end  	 NN	O
point 	point 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Subgroup  	Subgroup  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
showed  	showed  	 VBD	O
fewer  	fewer  	 JJR	O
treatment  	treatment  	 NN	B-NP
failures  	failures  	 NNS	I-NP
for  	for  	 IN	I-NP
LCPT  	LCPT  	 NNP	I-NP
versus  	versus  	 CC	O
IR-Tac  	IR-Tac  	 JJ	B-NP
among  	among  	 IN	O
black 	black 	 JJ	O
,  	,  	 ,	O
older 	older 	 JJR	O
,  	,  	 ,	O
and  	and  	 CC	O
female  	female  	 JJ	O
recipients 	recipients 	 NNS	O
.  	.  	 .	O
Safety  	Safety  	 NNP	O
was  	was  	 VBD	O
similar  	similar  	 JJ	O
between  	between  	 IN	O
groups 	groups 	 NNS	O
.  	.  	 .	O
From  	From  	 IN	O
month  	month  	 NN	O
1 	1 	 CD	O
,  	,  	 ,	O
TDD  	TDD  	 NNP	B-NP
was  	was  	 VBD	O
lower  	lower  	 JJR	O
for  	for  	 IN	O
LCPT 	LCPT 	 NNP	B-NP
;  	;  	 :	O
the  	the  	 DT	O
difference  	difference  	 NN	O
increased  	increased  	 VBN	O
over  	over  	 IN	O
time 	time 	 NN	O
.  	.  	 .	O
At  	At  	 IN	O
month  	month  	 NN	O
24 	24 	 CD	O
,  	,  	 ,	O
mean  	mean  	 JJ	O
TDD  	TDD  	 NN	B-NP
for  	for  	 IN	I-NP
LCPT  	LCPT  	 NNP	I-NP
was  	was  	 VBD	O
24 	24 	 CD	O
%  	%  	 NN	O
lower  	lower  	 JJR	O
than  	than  	 IN	O
for  	for  	 IN	O
the  	the  	 DT	O
IR-Tac  	IR-Tac  	 JJ	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
P  	P  	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
but  	but  	 CC	O
troughs  	troughs  	 NNS	O
were  	were  	 VBD	O
similar  	similar  	 JJ	O
( 	( 	 -LRB-	O
means  	means  	 NNS	O
at  	at  	 IN	O
24  	24  	 CD	O
months 	months 	 NNS	O
:  	:  	 :	O
LCPT 	LCPT 	 NNP	B-NP
,  	,  	 ,	O
5.47  	5.47  	 CD	O
±  	±  	 CD	O
0.17  	0.17  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
mL 	mL 	 NN	I-NP
;  	;  	 :	O
IR-Tac 	IR-Tac 	 NNP	B-NP
,  	,  	 ,	O
5.8  	5.8  	 CD	O
±  	±  	 CD	O
0.30  	0.30  	 CD	O
ng 	ng 	 CD	B-NP
/ 	/ 	 CD	I-NP
mL 	mL 	 NN	I-NP
;  	;  	 :	O
P=0.4 	P=0.4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Trial  	Trial  	 NN	B-NP
participant  	participant  	 NN	I-NP
eligibility  	eligibility  	 NN	I-NP
criteria  	criteria  	 NNS	I-NP
may  	may  	 MD	O
limit  	limit  	 VB	O
the  	the  	 DT	O
generalizability  	generalizability  	 NN	B-NP
of  	of  	 IN	O
results  	results  	 NNS	O
to  	to  	 TO	O
the  	the  	 DT	O
global  	global  	 JJ	O
population  	population  	 NN	O
of  	of  	 IN	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
kidney  	kidney  	 FW	I-NP
transplant  	transplant  	 FW	I-NP
recipients 	recipients 	 FW	I-NP
.  	.  	 .	O
Results  	Results  	 NNS	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
once-daily  	once-daily  	 JJ	B-NP
LCPT  	LCPT  	 NN	I-NP
in  	in  	 IN	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
kidney  	kidney  	 FW	I-NP
transplantation  	transplantation  	 FW	I-NP
has  	has  	 VBZ	O
comparable  	comparable  	 JJ	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
to  	to  	 TO	O
that  	that  	 DT	O
of  	of  	 IN	O
IR-Tac 	IR-Tac 	 JJ	B-NP
.  	.  	 .	O
Lower  	Lower  	 JJR	B-NP
TDD  	TDD  	 NNP	I-NP
reflects  	reflects  	 VBZ	O
LCPT 	LCPT 	 NNP	O
's  	's  	 POS	O
improved  	improved  	 JJ	O
bioavailability  	bioavailability  	 NN	B-NP
and  	and  	 CC	O
absorption 	absorption 	 NN	O
.  	.  	 .	O
